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1. Introduction 
Over the last two decades open radical cystectomy and urinary diversion have become a 
widely accepted form of treatment in both men and women with transitional cell carcinoma 
of the bladder. In the mid-1980s orthotopic urinary diversion with anastomosis to the 
urethra became an oncologically and functionally acceptable option in appropriately 
selected male patients. With better understanding of the anatomy and of the continence 
mechanism, orthotopic urinary diversion was subsequently performed in the early 1990s in 
female patients1.  
Until today open radical cystectomy is still considered the gold standard treatment for 
patients with muscle-invasive transitional cell carcinoma of the bladder 2, 3. This is based on 
the following observations: First, the best long-term survival rates and lowest local 
recurrence rates have been reported after radical cystectomy 4 5. Second, the morbidity and 
mortality of radical cystectomy have significantly improved during the last decades, and 
good functional results in patients with orthotopic urinary diversions have been achieved 6 
7. Third, radical cystectomy and pelvic lymph node dissection provides the most accurate 
tumor staging, thus helps selecting patients for adjuvant treatment protocols 8 9.  
Radical cystectomy performed through a laparoscopic approach was first described in 1992 
10. Since then, laparoscopic radical cystectomy has been reported in over 500 patients and 
current results suggest that this approach may cause less blood loss, decreased 
postoperative pain and faster recovery compared to open surgery 11 12. However, due to the 
technical difficulty (two-dimensional laparoscopic view, counterintuitive motion, poor 
ergonomics, and nonwristed instrumentation), the steep learning curve and the lack of long-
term oncological results, this treatment has not been adopted by mainstream urology.  
The introduction of robot assisted surgery for pelvic laparoscopy, especially in performing 
radical prostatectomy, has changed the possibilities of performing complicated operations in 
the small pelvis. Three-dimensional vision with ten-fold magnification and the dexterity 
provided by the endo-wrist (six degrees of freedom) allows the surgeon to operate the tips 
of the laparoscopic instruments like an open surgeon 13. Thus, the surgeon will benefit from 
a faster learning curve as compared to conventional laparoscopy. Further, these advantages 
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have allowed surgeons to translate standard open surgical procedures to a minimally 
invasive approach, especially its potential in operating in a narrow pelvis as well as for the 
reconstruction of the urinary tract.  
With the beginning of robot-assisted pelvic surgery a decade ago, radical cystectomy and 
reconstruction of the urinary tract is currently possible. However, until today, results on 
robot-assisted radical cystectomy (RARC) are mainly reported from a few centers 
worldwide. Further, results on RARC with intracorporeal urinary diversion are sparse, as 
most surgeons perform the reconstructive part outside the abdomen due to technical 
difficulties and longer operative time.  
2. Robot-assisted radical cystectomy 
The history of robot-assisted radical cystectomy started with Beecken et al. who was the first 
to perform a RARC with intracorporeal formation of an ileal orthotopic bladder substitute in 
2002 14. Operating time was 8.5 hours and blood loss 200ml. At five months post-operatively 
the oncological and functional result of the reservoir were considered excellent. Menon et al. 
reported the first series of RARC in 17 patients in 2003 15. In their series, an ileal conduit was 
performed in three patients, a W-pouch in ten, a double chimney in two, and a T-pouch in 
two cases. Mean operating time for radical cystectomy was 140 min and 120–168 min for the 
different urinary diversions, which were all performed extracorporeally. Mean blood loss 
was less than 150 mL, and surgical margins were negative in all cases.  
Since then, several case series have been published, however, most RARC series comprise 
less than 100 cases per center [table 1]. Additionally, our current knowledge on RARC is 
mainly based on reports from less than twenty different surgical centers worldwide. In 
order to provide a better overview on the value of RARC, data from a mix of 15 academic 
and private centers from the USA and Europe are prospectively collected and the results 
reported by the International Robotic Cystectomy Consortium (IRCC) 16 17 18. Despite 
increasing evidence that RARC seems as effective as open radical cystectomy, it is still too 
premature to draw any firm conclusions about the status of RARC.  
3. Patient selection 
Which patients are suitable for RARC using a minimal invasive approach? As patients 
planned for radical cystectomy are in general older and have a higher prevalence of 
smoking-related co-morbidities, pulmonary diseases may cause intraoperative problems. 
Some of these patients may even not be suitable for robot-assisted interventions because of 
the need for CO2 insufflation and the steep Trendelenburg position. The cardiac and 
respiratory systems are especially vulnerable to the extreme and lengthy head-down 
position. However, in order to minimize these risks, a 25° Trendelenburg position during 
radical cystectomy and lymph node dissection is possible without affecting the surgical 
quality 19. For the urinary diversion the Trendelenburg position can further be decreased to 
15°, thus minimizing potential pulmonary complications.  
A question mark regarding contra-indications in selecting patients for RARC remains. 
Presence of bulky disease, locally advanced disease, or enlarged lymph nodes have been 
considered relative contra-indications 20 21. Khan et al. reported specific surgery-related 
complications at RARC 22. They found that patients with multiples intravesical therapies, 
such as mitomycin or BCG, are more likely to have adhesions between the bladder and the 
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n. a. not available, # report on 4 female pts., ≠one case without urinary diversion, renal failure, ǂ results 
from pts. < 70years vs. ≥ 70 years) 
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Table 1. Contemporary reports/series of robotic-assisted laparoscopic radical cystectomy 
(RARC) and urinary diversion for TCC of the bladder. 
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surrounding structures, especially the rectum, rendering dissection difficult. Thus, careful 
dissection is required in developing the rectovesical plane to avoid injury of the rectum. 
Prior abdominal surgery, radiotherapy or neoadjuvant chemotherapy may be relative-
contraindications for RARC, as these factors can significantly increase the degree of 
technical difficulty  22 23. 
Patient selection makes a direct comparison between open radical cystectomy series and 
smaller RARC series difficult. Results from open high-volume centers indicate that 
approximately two-thirds of patients at radical cystectomy have organ-confined disease, 
whereas one-third has non-organ-confined disease 24 25 26 27 28 29. In general, the percentage of 
patients with non-organ-confined disease undergoing RARC is substantially lower than 
figures reported from major series from open radical cystectomy [table 2] 30 31 32 21, 33-40. 
Recent multi-institutional results from the International Robotic Cystectomy Consortium 
(IRCC) of 527 patients treated with RARC show similar figures regarding the numbers of 
patients with organ-confined (65%) vs. non-organ-confined (35%) disease, as with open 
radical cystectomy series 18. However, data on neoadjuvant chemotherapy were not 
reported in this series.  
4. Surgery-related complications 
Although the number of RARC cases reported in the literature is relatively small, the 
intraoperative complication rate seems comparable to open radical cystectomy series. Nix et 
al. found in a prospective randomized trial of robotic (n = 21) versus open (n = 20) radical 
cystectomy no difference in the absolute number of complications (p = 0.279) 41. Less blood 
loss was observed in the robotic group (mean 258 mL) compared to the open group (mean 
575 mL). Similarly, Wang et al. reported no difference regarding intraoperative 
complications in their prospective trial between robotic (n = 33) and open radical cystectomy 
(n = 21) 32. Again, less blood loss was noted with RARC (mean 400 mL, range 100–1200 mL) 
compared to open radical cystectomy (mean 750 mL, range 250–2500 mL). Galich et al., in a 
comparative analysis of early postoperative outcomes following robotic (n = 13) and open (n 
= 24) radical cystectomy, found no difference between groups regarding surgery-related 
complications and blood loss 33. Kauffman et al. collected data on 79 consecutive patients 
treated with RARC and extracorporeal urinary diversion 42. In their series, high-grade 
complications (Clavien III–V) occurred in 16 patients (21%) during the first 3 months 
postoperatively. Urinary obstruction, intra-abdominal abscess, uro-enteric fistulas, and 
gastrointestinal bleeding were the most common high-grade complications. The high 
percentage of overall urinary obstruction (8%) despite extracorporeal urinary diversion 
without robotic assistance is of concern 42. Khan et al. reported an 8% ureteric stricture rate, 
with 6% strictures occurring on the left side in their series of 50 RARC cases 22. Results from 
open radical cystectomy series report an uretero-intestinal stricture rate of less than 3% 5. 
Performing the anastomosis between the ureters and the urinary diversion outside the 
abdomen through a small abdominal incision may only be possible with relatively long 
ureters, thus increasing the risk for ischemic complications. Resection of the ureters at the 
level where they cross over the common iliac artery minimizes the risk of strictures at the 
uretero-intestinal anastomosis due to ischemia 43.  
Different parameters may affect outcome and risk for surgery-related complications such as 
age, higher ASA score or previous surgery. Butt et al. did not find a significant association 
between age, BMI, ASA score and complication rate in their series of 66 RARC cases 44. 
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n. a. not available; * 91% of pts with FU > 3 years; # results on 4 female cases; ≠58 pats eligible for analysis 
Table 2. Patient characteristic of contemporary robotic-assisted radical cystectomy (RARC) 
and open radical cystectomy series for TCC of the bladder. 
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Similar, Coward et al. did not find worse outcomes in terms of complications when 
comparing older patients (≥ 70 years) with higher ASA scores vs. younger patients (< 70 
years) treated with RARC 45.  
Schumacher et al. assessed the surgery-related complications at RARC with total 
intracorporeal urinary diversion during their learning curve 35. A total of 45 patients were 
pooled in 3 consecutive groups of 15 cases each to evaluate the complications according to 
the Clavien classification 46. Overall, fewer complications were observed between the groups 
over time, with a significant decrease in late versus early complications (P = 0.005 and P = 
0.058). However, the early Clavien grade III complications remained significant (27%) and 
did not decline with time; thus indicating the complexity of the intracorporeal urinary 
diversion. Khan et al., assessed early surgery-related complications using also the Clavien 
Classification 22. Early complications were observed in 34% of patients. Clavien grade IIIa/b 
complications were seen in 29% of their patients. Both series have somehow a lower 
complication rate compared to the 64% complication rate from a large series of 1142 open 
radical cystectomy patients from the Memorial-Sloan-Kettering Cancer Center (MSKCC) 47. 
The higher percentage of non-organ-confined tumors in the open series from MSKCC may 
be one factor to explain this difference in favor of the robotic approach. 
Hayn et al., from the IRCC assessed whether previous robotic surgical experience affects on 
the implementation and execution of robot-assisted radical cystectomy 17. They found that 
previous robot-assisted radical prostatectomy (RARP) case volume might affect the 
operative time, blood loss, and lymph node yield at RARC. In addition, surgeons with 
increased RARP experience operated on patients with more advanced tumors. Previous 
RARP experience, however, did not appear to affect the surgical margin status. 
5. Lymphadenectomy 
Pelvic lymphadenectomy at radical cystectomy is the standard treatment for patients with 
muscle-invasive bladder cancer. Radical cystectomy series report that approximately 25% of 
patients initially staged T1–T4 N0 M0 who undergo lymphadenectomy have lymph node 
metastases; and the absolute number of positive nodes removed affects survival 9 48. 
It has been stated that, as a guideline, removal of >20 nodes per patient should be the aim 48. 
Others have reported an improved cancer-specific survival rate of 65% when ≥ 16 nodes 
were retrieved compared to 51% when < 16 nodes were retrieved 49. Whereas some experts 
do recommend that at least 10 nodes should be removed at pelvic lymph node dissection 50 
51. While assessing the lymph node counts obtained after lymph node dissection at radical 
cystectomy from various institutional series, huge differences in node count are noted. 
Median node count has been reported to vary from 8 to 80, and is also affected by the extent 
of a pelvic lymphadenectomy 9 24 52 53 47 48 54 55 56 57 58. Interindividual variances, sending 
separate or en-bloc nodal packages, and the pathologic work-up of the specimens may 
explain differences in reporting on the number of nodes removed/detected by the 
pathologist 58 59. Other factors such as the commitment of the surgeon in performing a 
lymph node dissection or selecting patients for more or less extensive lymphadenectomy 
may explain differences in nodal count 60.  
Controversy still persists regarding the boundaries and terminology used in lymph node 
dissection. Mills et al. describe a standard lymph node dissection that includes removal of 
nodal tissue up to and including the common iliac bifurcation, including the internal iliac 
vessels, presacral area, obturator fossa, external iliac vessels, and distal part of the common 
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iliac artery 61. In order to avoid injury to the hypogastric nerves, nodes medial to the ureter 
(proximal half of the common iliac artery, aortic bifurcation) are not removed. In contrast, 
Stein et al. define an extended lymph node dissection as including all nodal tissue in the 
boundaries of: the aortic bifurcation and common iliac vessels (proximally); the 
genitofemoral nerve (laterally); the circumflex iliac vein and lymph node of Cloquet 
(distally); the hypogastric vessels (posteriorly), including the obturator fossa, pre-sciatic 
nodes bilaterally; and the presacral lymph nodes anterior to the sacral promontory 62. 
Data on lymph node yield and oncological outcome in RARC series are still limited, 
however, node counts are similar to open radical cystectomy series 21 31 35 34 36 63. Earlier 
reports from various RARC series describe mostly the boundaries of a limited (obturator 
fossa only) or standard template with less than a median of 20 nodes removed 63. A recent 
report by Pruthi et al. performing an extended lymph node dissection, described a median 
node yield of 28 nodes (range 12–39) 64. Schumacher et al. found similar node counts in their 
series of 45 patients with a mean of 22.5 nodes (range 10 - 52) removed 35. Applying a 
template up to the aortic bifurcation resulted in a mean of 32 nodes removed. Richards et al. 
compared lymph node counts from 35 open radical cystectomy cases to their first 35 RARC 
cases 65. Median total lymph node yield was similar between groups, with 15 nodes (range 
11 - 22) in the open cystectomy group compared to 16 nodes (range 11 - 24) in the RARC 
group. Lavery et al, reported in their first 15 RARC cases undergoing an extended pelvic 
lymphadenectomy up to the aortic bifurcation a mean nodal yield of 41.8 nodes (range 18 - 
67) 66. Kauffmann et al. applying a similar template at RARC found a mean of 19.1 nodes 
(range 0 - 56) removed 42. Evaluating the number of nodes removed from different 
institutions, the IRCC reported that at RARC 82.9% underwent a pelvic lymphadenectomy, 
which resulted in a mean of 17.8 nodes (range 0 - 68) removed 18.  According to these 
reports, it seems that robotic lymphadenectomy applying an extended lymph node dissection 
template, if indicated, up to the aortic bifurcation is technically feasible with intraoperative 
morbidity similar to open series 63. 
6. Urinary diversion 
The first case of RARC with intracorporeal urinary diversion was performed by Beecken et 
al. in 2002 14. Operative time was 8.5 hours, and therefore attention was turned towards 
extracorporeal urinary diversion in order to decrease operative times. Menon et al. were the 
first to describe their technique of extracorporeal diversion, using a 5–8 cm mid-line incision 
15. Until today, the majority of urinary diversions in conjunction with RARC are done 
extracorporeally [table 1] 67. However, standardization of the intracorporeal procedure and 
decreasing operative times might turn the interest towards this approach 19 68. We have 
previously reported our results in a series of 18 patients treated with RARC and totally 
intracorporeal urinary diversion, later, results in 45 patients were published 19 35. Mean 
operative time was 476 min (range 325–760) and mean blood loss 669 mL (range 200–2200) 
35. Whether there is an advantage of performing the complete procedure intracorporeally or 
not is less clear. At least in female patients, the specimen can be removed through an 
incision via the vaginal wall, thus avoiding a mid-line incision. The technical difficulties in 
performing the urinary diversion totally intracorporeally have so far prevented its wide-
spread adoption. Results reported by Schumacher and co-workers indicate at least at the 
beginning of their learning curve increased surgery-related complications using an 
intracorporeal urinary diversion approach 35. Rehman et al. reported on 9 patients treated 
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with RARC and totally intracorporeal confection of an ileal conduit 69. One postoperative 
iatrogenous necrosis of the ileal conduit, probably caused by retraction of the organ bag 
occurred.  
7. Oncologic outcome 
To objectively assess oncological outcomes in patients treated either with open radical 
cystectomy or RARC for bladder cancer one needs to focus on: long-term cancer control, 
surgical quality (positive margins), tumor spillage, and port site metastasis.  
Today, the highest long-term survival rates were reported for open radical cystectomy with 
an extended lymph node dissection. Stein et al. reported 5-year and 10-year recurrence-free 
survival rates of 68% and 60%, respectively, among 1,054 patients treated with radical 
cystectomy and extended lymph node dissection with curative intent 24. For lymph node-
negative, organ-confined disease, 5-year and 10-year recurrence-free survival rates were 
85% and 82%. Similar results have been reported from other high-volume centers 
performing open radical cystectomy 25 26 27 28 29.  
Whether the same cancer control rates equivalent to results from open radical cystectomy 
series can be achieved with RARC is still unknown; to date there are no long-term data 
available 70. Median time to any recurrence after radical cystectomy is approximately 12 
months, whereas 86% of recurrences occur within 3 years 24. The mean follow-up in the 
current RARC series ranged from 3 to 77 months [tables 1 and 2]. However, in all of these 
RARC series median follow-up is short (<24 months), and reported survival data in which 
all patients have passed at least a 12 months follow-up do not exist. 
The surgical quality at radical cystectomy independent of the surgical approach is essential 
for optimal local cancer control. Thus, negative margins must be achieved to avoid local 
tumor recurrence, which ultimately results in the death of the patient. Positive surgical 
margins have been reported to be 5% or less in high-volume open radical cystectomy series 
25 26 27 28 29. The incidence of positive margins at RARC ranged from 0% to 13% 21 30 31 32 34 36 37 
38 39 40 71 72. Guru et al, reported a 10.3% positive margin rate at RARC, whereas Yuh et al. 
found 13% positive margins in their patients 36 40. Whether this high positive margin rate is 
attributable to the learning curve in these series is not clear. Data from the IRCC showed an 
overall 7% positive margin rate in their pooled 496 patients 17. For patients with pathologic 
stage ≤ T3, 3.7% had a positive margin, whereas for patients with pathologic stage T3 or T4, 
16% had a positive margin. The authors found with increasing surgical experience at RARC 
an improvement of their positive margin rate 17. 
Port site metastasis in urological malignancies are of concern; they do occur, albeit 
infrequently. The etiology of port site metastasis is unknown. Port site metastasis has been 
reported after RARC and laparoscopic radical cystectomy for bladder cancer 73 74. 
8. Post-operative recovery 
Perioperative pathophysiology and care suggest that a multitude of factors contribute to 
postoperative morbidity, length of hospital stay, and convalescence in patients undergoing 
surgery 75. Radical cystectomy is still associated with significant perioperative morbidity—
this despite the implementation of accelerated postoperative recovery programs, or so-
called “fast-track” surgery 76. Comparison between historical cystectomy series and recent 
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studies regarding post-operative recovery are difficult, as the concept of “fast-track” surgery 
has only been adopted by the urologic community during the last decade.   
In order to reduce perioperative morbidity at cystectomy, Pruthi and co-workers have 
implemented and continuously improved the perioperative management in their 362 
patients 77. Reported findings from the last 100 (open and RARC) of these 362 cystectomy 
cases showed favorable return of bowel function (mean time to flatus 2.2 days, and mean 
time to bowel movements 2.9 days), the majority of patients being discharged after a mean 
of 5 days. Readmission was observed in 12% of patients, and the most common reasons for 
readmission were urinary tract infection (3%), gastrointestinal disorders (2%), and deep 
venous thrombosis (2%). The same group has published a randomized trial and assessed 
perioperative outcomes in patients treated with open versus robotic radical cystectomy 41. 
Patients undergoing robotic cystectomy had longer operative times (4.2 versus 3.5 hours; p < 
0.001) and less blood loss (258 versus 575 mL; p < 0.001) than did patients with open 
cystectomy. Further, patients in the robotic group demonstrated a faster return of bowel 
activity (median time to flatus 2.3 days versus 3.2 days, and time to bowel movement 3.2 
days versus 4.3 days). Hospital stay did not differ between groups (robotic 5.1 days, open 
6.0 days; p = 0.239). Patients in the robotic group required significantly less analgesia than 
did patients with the open approach (p = 0.019). Similar results have been reported by Ng et 
al., comparing 104 open cystectomy with 83 RARC cases 78. The robotic group demonstrated 
decreased blood loss (460 mL versus 1172 mL; p < 0.0001) and shorter length of hospital stay 
(5.5 days versus 8 days; p < 0.0001) than did the open cystectomy group. Wang et al., 
comparing open radical cystectomy with RARC patients, reported reduced blood loss, faster 
return to regular diet, and shorter hospital stay in the robotic group 32. One may argue that 
fewer non-organ-confined tumors (28%) in the RARC group may have influenced their 
results compared to 57% non-organ-confined tumors in the open group. A recent study by 
Coward et al. found similar results regarding time to flatus (median 2 days) and time to 
bowel movements (median 3 days) after RARC in their series 45.  
Despite the presumed advantages of less postoperative pain, faster return of bowel 
movements, shorter hospital stay, and overall quicker recovery over open surgery, the exact 
role of laparoscopy in improving perioperative outcomes remains unclear.   
9. Quality of life 
Quality of life (QoL) and postoperative recovery after surgery are important factors with 
direct financial implications for the health care system. Karvinen et al. reported on the effect 
of exercise and QoL in survivors of bladder cancer 79. Findings from their study indicate that 
exercise is positively associated with QoL and the ability to perform physical activity results 
in increased QoL. If patients are able to return more quickly to preoperative levels with 
minimally invasive surgery, i.e. robotic surgery, they might be able to initiate exercise 
sooner, which in turn improves their QoL.  
Yuh et al. evaluated QoL in a small single-center study after RARC 20. Despite some 
inheriting limitations of the study design, QoL appeared to return to base-line by 3 months 
after RARC, and improved further at 6 months. The authors postulated that short-term 
improvement in QoL might also have positive implications regarding initiating adjuvant 
treatment protocols in these patients. Further studies are required to assess the physical and 
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psychological implications of robotic surgery on QoL in patients undergoing radical 
cystectomy.  
Functional results have been reported after open nerve-sparing radical cystectomy and 
orthotopic bladder substitution, however, reports from RARC series assessing continence 
and potency rates are sparse 7 80. 
10. Costs 
The introduction of new and costly technologies into daily clinical practice has been 
criticized, especially during periods of economic uncertainty. With the introduction of 
expensive robotic technology cost-effectiveness has become more important. For robot-
assisted radical prostatectomy some studies have shown volume-dependant cost advantages 
81 82. Less information on cost-analysis is available for RARCS.  
Smith et al., from North Carolina, US, performed a cost analysis at their institution between 
robotic and open radical cystectomy 83. The financial costs of robotic and open radical 
cystectomy were categorized into operating room and hospital components, and further 
divided into fixed and variable costs for each. Variable costs were related to several factors, 
such as length of hospital stay. For each procedure the means of 20 cases were used to 
perform a comparative cost analysis. Based on their results, robotic cystectomy is associated 
with an overall higher financial cost of $1,640.  
Martin et al. performed a detailed cost-analysis for open radical cystectomy vs. RARC cases  
84. They found that the most critical parameters for increased costs were operative time and 
hospital stay, which favored the robotic approach at their institution. Further, they stated 
that the real cost advantages are mostly seen when indirect costs are considered, such as 
treatment of perioperative complications or readmission rates due to complications.  
Costs are difficult to measure and comprise other factors than just the perioperative period. 
Thus, earlier return to normal activity and reduced sick-leave might be important factors 
justifying these additional costs offered by the robotic approach.  
11. Conclusions 
Based on the current literature RARC is evolving rapidly as an alternative technique to open 
surgery in patients requiring radical cystectomy and urinary diversion. Lymph node yield 
and perioperative outcomes are similar to open radical cystectomy series; however, long-
term oncological results are unknown. Several small prospective or randomized single-
center trials showed comparable results between RARC and open cystectomy. However, the 
surgical procedure is technically demanding, especially when performing the urinary 
diversion totally intracorporeal. It is advisable to concentrate this type of surgery to high-
volume centers where robotic expertise and technology is available.   
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